A retrospective cohort study of effect of repeated onabotulinum neurotoxin A injections for the treatment of drooling in children with neurodisabilities
Latest Information Update: 25 Oct 2021
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Sialorrhoea
- Focus Therapeutic Use
Most Recent Events
- 25 Oct 2021 New trial record
- 01 Aug 2021 Primary endpoint (VAS at the 8-week assessment) has been met, according to Results published in the Developmental Medicine and Child Neurology.
- 01 Aug 2021 Primary endpoint (drooling quotient) has been met, according to Results published in the Developmental Medicine and Child Neurology.